Literature DB >> 8403210

Isoenzyme shift from glucokinase to hexokinase is not an early but a late event in hepatocarcinogenesis.

F Klimek1, P Bannasch.   

Abstract

The appearance of hepatocellular adenomas and carcinomas induced in rat liver with N-nitrosomorpholine is preceded by different types of preneoplastic foci consisting of phenotypically altered hepatocytes. The altered cells show changes in the activities of various enzymes including those of carbohydrate metabolism. Glucokinase is a type of hexokinase that is specific for hepatocytes. The enzyme plays a key role in glucose homeostasis in normal liver parenchyma and is replaced in the dedifferentiated hepatocytes of carcinomas by a low Km hexokinase. To determine the time course of the shift from glucokinase to this isoenzyme in the development of carcinomas, focal hepatic lesions were dissected from freeze-dried serial tissue sections by the laser-dissection method and studied by microbiochemical tests. In early clear and acidophilic cell foci that excessively stored glycogen (glycogenotic foci) a nearly normal glucokinase activity comparable with that of the surrounding hepatocytes was observed, whereas in the later appearing mixed cell foci a reduction in the activity of this enzyme without a compensatory increase in the hexokinase activity was found. A pronounced activity of hexokinase was only measurable in fully developed carcinomas. Since glucokinase is not modified at the post-transcriptional level, a gradual decrease in its mRNA during hepatocarcinogenesis can be assumed. A shift in gene expression from glucokinase to the isoenzyme hexokinase occurs only at the mixed cell foci/carcinoma transition step of the carcinogenic process.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8403210     DOI: 10.1093/carcin/14.9.1857

Source DB:  PubMed          Journal:  Carcinogenesis        ISSN: 0143-3334            Impact factor:   4.944


  8 in total

1.  Overexpression of insulin receptor substrate-1 emerges early in hepatocarcinogenesis and elicits preneoplastic hepatic glycogenosis.

Authors:  D Nehrbass; F Klimek; P Bannasch
Journal:  Am J Pathol       Date:  1998-02       Impact factor: 4.307

2.  Microheterogeneity of cytosolic and membrane-bound hexokinase II in Morris hepatoma 3924A.

Authors:  A Rempel; P Bannasch; D Mayer
Journal:  Biochem J       Date:  1994-10-01       Impact factor: 3.857

3.  Glycogenotic hepatocellular carcinoma with glycogen-ground-glass hepatocytes: a heuristically highly relevant phenotype.

Authors:  Peter Bannasch
Journal:  World J Gastroenterol       Date:  2012-12-14       Impact factor: 5.742

4.  Hepatocellular neoplasms induced by low-number pancreatic islet transplants in streptozotocin diabetic rats.

Authors:  F Dombrowski; P Bannasch; U Pfeifer
Journal:  Am J Pathol       Date:  1997-03       Impact factor: 4.307

Review 5.  Early bioenergetic changes in hepatocarcinogenesis: preneoplastic phenotypes mimic responses to insulin and thyroid hormone.

Authors:  P Bannasch; F Klimek; D Mayer
Journal:  J Bioenerg Biomembr       Date:  1997-08       Impact factor: 2.945

6.  Altered liver acini induced in diabetic rats by portal vein islet isografts resemble preneoplastic hepatic foci in their enzymic pattern.

Authors:  F Dombrowski; E Filsinger; P Bannasch; U Pfeifer
Journal:  Am J Pathol       Date:  1996-04       Impact factor: 4.307

7.  Over-expression of glucose transporter isoform GLUT1 and hexokinase I in rat renal oncocytic tubules and oncocytomas.

Authors:  Y S Ahn; A Rempel; H Zerban; P Bannasch
Journal:  Virchows Arch       Date:  1994       Impact factor: 4.064

8.  Metabolic Alteration in Hepatocellular Carcinoma: Mechanism of Lipid Accumulation in Well-Differentiated Hepatocellular Carcinoma.

Authors:  Hideo Suzuki; Motoyuki Kohjima; Masatake Tanaka; Takeshi Goya; Shinji Itoh; Tomoharu Yoshizumi; Masaki Mori; Mariko Tsuda; Motoi Takahashi; Miho Kurokawa; Koji Imoto; Shigeki Tashiro; Akifumi Kuwano; Masaki Kato; Seiji Okada; Makoto Nakamuta; Yoshihiro Ogawa
Journal:  Can J Gastroenterol Hepatol       Date:  2021-02-18
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.